Research Article
Recurrent Neoantigens in Colorectal Cancer as Potential Immunotherapy Targets
Table 1
Summary of clinical information of CRC cohort, including patients from seven studies.
| | Characteristic | Baylor | Beijing | COCA-CN | Genetech | Harvard | TCGA | Texas | Total | | () | () | () | () | () | () | () | () |
| | Age (years) | | | | | | | | | | <60 | 38 (34.5%) | 48 (49.0%) | 155 (48.3%) | 0 (0%) | 67 (10.8%) | 158 (29.9%) | 0 (0%) | 466 (26.2%) | | ≥60 | 70 (63.6%) | 50 (51.0%) | 166 (51.7%) | 0 (0%) | 550 (88.9%) | 366 (69.3%) | 0 (0%) | 1202 (67.6%) | | Unknown | 2 (1.8%) | 0 (0%) | 0 (0%) | 74 (100%) | 2 (0.3%) | 4 (0.8%) | 29 (100%) | 111 (6.2%) | | Sex | | | | | | | | | | Female | 65 (59.1%) | 50 (51.0%) | 127 (39.6%) | 0 (0%) | 380 (61.4%) | 253 (47.9%) | 15 (51.7%) | 890 (50.0%) | | Male | 45 (40.9%) | 48 (49.0%) | 194 (60.4%) | 0 (0%) | 239 (38.6%) | 273 (51.7%) | 14 (48.3%) | 813 (45.7%) | | Unknown | 0 (0%) | 0 (0%) | 0 (0%) | 74 (100%) | 0 (0%) | 2 (0.4%) | 0 (0%) | 76 (4.3%) | | Stage | | | | | | | | | | I | 12 (10.9%) | 10 (10.2%) | 40 (12.5%) | 0 (0%) | 152 (24.6%) | 94 (17.8%) | 0 (0%) | 308 (17.3%) | | II | 42 (38.2%) | 44 (44.9%) | 94 (29.3%) | 0 (0%) | 187 (30.2%) | 196 (37.1%) | 0 (0%) | 563 (31.6%) | | III | 48 (43.6%) | 39 (39.8%) | 130 (40.5%) | 0 (0%) | 159 (25.7%) | 150 (28.4%) | 1 (3.4%) | 527 (29.6%) | | IV | 8 (7.3%) | 4 (4.1%) | 56 (17.4%) | 0 (0%) | 65 (10.5%) | 69 (13.1%) | 28 (96.6%) | 230 (12.9%) | | Unknown | 0 (0%) | 1 (1.0%) | 1 (0.3%) | 74 (100%) | 56 (9.0%) | 19 (3.6%) | 0 (0%) | 151 (8.5%) | | MSI status | | | | | | | | | | MSI-H | 24 (21.8%) | 8 (8.2%) | 0 (0%) | 15 (20.3%) | 91 (14.7%) | 65 (12.3%) | 0 (0%) | 203 (11.4%) | | MSI-L | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 77 (14.6%) | 0 (0%) | 77 (4.3%) | | MSS | 81 (73.6%) | 32 (32.7%) | 0 (0%) | 59 (79.7%) | 438 (70.8%) | 346 (65.5%) | 29 (100%) | 985 (55.4%) | | Unknown | 5 (4.5%) | 58 (59.2%) | 321 (100%) | 0 (0%) | 90 (14.5%) | 40 (7.6%) | 0 (0%) | 514 (28.9%) |
|
|
